Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
The purpose of this study is to generate hypotheses regarding the safety, efficacy, and immunological impact of cladribine tablets after treatment with natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS)…
- Trial name
- NCT04178005
- Testing
- Cladribine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis
Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
The purpose of this study is to test a novel strategy to prevent the clinical problem of secondary autoimmunity following alemtuzumab treatment of multiple sclerosis.
- Trial name
- CAM-THY (NCT01712945)
- Testing
- Palifermin, Alemtuzumab
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Parkinson's Disease, Multiple Sclerosis
Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients
Fatigue is one of the most common and debilitating symptoms experienced in Parkinson's Disease (PD) and Multiple Sclerosis (MS).
- Trial name
- PDMSLac (NCT02184494)
- Testing
- pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Florida State University
Multiple Sclerosis, Parkinson Disease
Intestinal Immunity in Neurologic Disease
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
- Conditions
- Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder
- Trial name
- NCT06329453
- Testing
- Colon Tissue Biopsy
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Yale University
Multiple Sclerosis
Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)
The researchers will use technology-assisted ambulatory assessment techniques to examine cognitive dysfunction in people with Multiple Sclerosis (MS).
- Trial name
- NCT05252195
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS)
The goal of this observational study is to learn about the role of kappa free light chains (KFLC) in cerebrospinal fluid (CSF) in the diagnosis of multiple sclerosis (MS) and clinically isolated syndrome (CIS).
- Trial name
- PRO-KFLC (NCT07183020)
- Testing
- Oligoclonal bands and kappa free light chains (KFLC)
- Where
- Germany
- Volunteers
- 1,142 people
- Sponsor
- Skripuletz, Thomas Prof. Dr.
Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis
OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis.
- Conditions
- Autoimmune Encephalitis (AE), Acute Disseminated Encephalomyelitis, Multiple Sclerosis
- Trial name
- O-MEG-A-MIND (NCT07689682)
- Testing
- OPM- Magnetoencephalography
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Aston University
Multiple Sclerosis
Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
The purpose of this study is to determine if treatment with Mirabegron will improve urinary urgency control beyond that achieved with pelvic floor exercises alone
- Trial name
- MIRROR (NCT02086188)
- Testing
- Mirabegron
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Theodore R. Brown, MD MPH
Neurogenic Bladder, Multiple Sclerosis
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
Neurogenic overactive bladder (NOAB), characterized by urinary frequency, urgency or urgency incontinence symptoms occurring during the storage phase of the bladder, is the most common urinary complaint in multiple sclerosis…
- Conditions
- Neurogenic Bladder, Multiple Sclerosis, Overactive Bladder
- Trial name
- MSBLADDER (NCT06072703)
- Testing
- Magstim Rapid2 System
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- The Methodist Hospital Research Institute
Multiple Sclerosis
Telerehabilitation in Multiple Sclerosis
The main aim of the study is to evaluate the efficacy of the Virtual Reality Rehabilitation System (VRRS, Khymeia) compared to usual care treatment for patients with MS at home.
- Trial name
- NCT03444454
- Testing
- VRRS Khymeia, Usual care program, VRRS Khymeia plus active tDCS
- Where
- Italy
- Volunteers
- 136 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Secondary-progressive Multiple Sclerosis
Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients
This will be a phase I, open, multicenter, international study performed by 3 participating centres across two countries (Italy and Switzerland).
- Trial name
- NSC-SPMS (NCT03282760)
- Testing
- Human Neural Stem Cells
- Where
- 3 sites in Italy, Switzerland
- Volunteers
- 24 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Multiple Sclerosis
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of…
- Trial name
- PASSAGE (NCT01442194)
- Testing
- other disease-modifying therapy, Fingolimod
- Where
- 238 sites in United States, Argentina and 5 more
- Volunteers
- 3,076 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose…
- Trial name
- VISTA (NCT06083753)
- Testing
- PIPE-307 Dose A, PIPE-307 Dose B
- Where
- 21 sites in United States
- Volunteers
- 182 people
- Sponsor
- Janssen Research & Development, LLC
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4)…
- Trial name
- NCT01892345
- Testing
- Eculizumab
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 143 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Sclerosis
Pathological Basis of MRI Signal Changes in Multiple Sclerosis
Background: Multiple sclerosis (MS) is a disease that damages the central nervous system (brain and spinal cord). This leads to increased physical disability over time. The disease is lifelong once it begins.
- Trial name
- NCT02659956
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
[18F]F-DED PET Imaging of Reactive Astrocytes in Multiple Sclerosis
Despite significant advancements in multiple sclerosis (MS) treatment over the past decade, a specific imaging biomarker for predicting disease progression remains lacking.
- Trial name
- F-DED PET MS (NCT07805473)
- Testing
- [18F]fluorodeprenyl-D2
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Parc de Salut Mar
Multiple Sclerosis
Investigation of the Effects of Technology Supported Different Physiotherapy Approaches on Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is an autoimmune disease characterized by chronic inflammation, demyelination and axonal loss of the central nervous system.
- Trial name
- NCT04891341
- Testing
- Technology Supported Task-Oriented Circuit Training, Home-based Telerehabilitation
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Hacettepe University
Multiple Sclerosis, Relapsing-Remitting
Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis
The aim of this study is to determine whether prophylactic vaccines recommended are effective and safe in patients with multiple sclerosis(MS) under MS-specific therapy.
- Trial name
- NCT02275741
- Testing
- prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- Dr. med. Micha Loebermann
Spinal Cord Injuries, Cerebral Palsy
LEAP a New Overground Body Weight Support Robot: Usability Trial
People with central nervous system disorders such as spinal cord injury, stroke, cerebral palsy, Parkinson's disease, multiple sclerosis, etc… often have impaired lower extremity function that limits activities of daily life and…
- Conditions
- Spinal Cord Injuries, Cerebral Palsy, Parkinson Disease, Multiple Sclerosis
- Trial name
- LEAP (NCT03458169)
- Testing
- Therapist LEAP session feedback, Participant LEAP session feedback, LEAP risk control validation
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Clinique Romande de Readaptation
Multiple Sclerosis
Vaccine Exposure in Patients With MS
Vaccines in MS patients have been controversial, in particular hepatitis B vaccine in the 90s and more recently human papillomavirus vaccine.
- Trial name
- Enquête Vaccin (NCT03191669)
- Testing
- Auto-questionnaire
- Where
- 6 sites in France
- Volunteers
- 335 people
- Sponsor
- Hospices Civils de Lyon